Sustainability Report 2014-2015
Total Page:16
File Type:pdf, Size:1020Kb
Roche Latin America Sustainability Report 2014-2015 Coordination, editing, and content verification Find out more: Edelman Graphic design and layout 2MCINE Data and photos provided by Roche Global and Roche country affiliates Roche Latin America Produtos Roche Químicos e Farmacêuticos S.A. Av. Engenheiro Billings, 1.729 – Jaguaré CEP 05321-900 – São Paulo/SP, Brazil All Rights Reserved Partial or total reproduction of this report is prohibited without the prior authorization of F. Hoffmann-La Roche Ltd Our global sustainability website at: http://www.roche.com/responsibility.htm Support with identification, provision and accuracy of content: Argentina Ecuador Productos Roche S. A. Q. e I. Roche Ecuador S.A. Rawson 3150, (B1610BAL), Ricardo Rojas, Tigre Av. 10 de Agosto N36-239 y Naciones Unidas, Casilla: 1711-06185 Província de Buenos Aires, Argentina Quito, Ecuador Brazil Mexico Produtos Roche Químicos e Farmacêuticos S.A. Productos Roche S. A. de C.V. Av. Engenheiro Billings, 1.729 – Jaguaré Cerrada de Bezares No. 9 CEP 05321-900 – São Paulo/SP, Brazil Col. Lomas de Bezares 11910, Mexico, D.F. Central America and the Caribbean Productos Roche S.A. Peru Zona Franca Ultrapark, Edificio 4 Roche Perú La Aurora, Heredia, Costa Rica San Isidro, Dionísio Derteano 144 of. 1301 Lima, Peru Chile Roche Chile Ltda. Uruguay Av. Cerro el Plomo 5630, Piso 12. Las Condes. Roche International Ltd Santiago, Chile WTC - Torre 4, Piso 5, Luis Bonavita, 1266 Montevideo, Uruguay Colombia Productos Roche S.A. Venezuela Carrera 44 No. 20-21 Produtos Roche S.A. Bogotá, Colombia Edificio Roche, Av. Diego Cisneros, Los Ruices Caracas, Venezuela 4 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 5 Welcome to our Sustainibility Report 2014-2015 Contents 1. This Report . 9 8. Colombia . 97 Roche Colombia at a Glance . 98 2. Global Overview . 11 Healthcare in Colombia . 99 Roche at a Glance . 11 Roche in Colombia . 99 Roche Group Profile. 15 Sustainability Initiatives . 101 Sustainability Strategy . 15 9. Ecuador . 109 3. Latin America . 25 Roche Ecuador at a Glance . 110 Roche Latin America at a Glance . 26 Healthcare in Ecuador . 111 Healthcare in Latin America . 29 Roche in Ecuador . 111 Roche in Latin America . 31 Sustainability Initiatives . 113 Sustainability Initiatives . 33 10. Mexico . 119 4. Argentina . 45 Roche Mexico at a Glance . 120 Roche Argentina at a Glance . 46 Healthcare in Mexico . 121 Healthcare in Argentina . 47 Roche in Mexico . 121 Roche in Argentina . 47 Sustainability Initiatives . 123 Sustainability Initiatives . 49 11. Peru . 131 5. Brazil . 59 Roche Peru at a Glance . 132 Roche Brazil at a Glance . 60 Healthcare in Peru . 133 Healthcare in Brazil . 61 Roche in Peru . 134 Roche in Brazil . 61 Sustainability Initiatives . 135 Sustainability Initiatives . 63 12. Uruguay . 143 6. Central America and the Caribbean . 73 Roche Uruguay at a Glance . 144 Roche Central America and the Caribbean at a Glance . 74 Healthcare in Uruguay . 145 Healthcare in Central America Roche in Uruguay . 145 and the Caribbean . 75 Sustainability Initiatives . 147 Roche in Central America and the Caribbean . 75 Sustainability Initiatives . 77 13. Venezuela . 157 Roche Venezuela at a Glance . 158 7. Chile . 85 Healthcare in Venezuela . 159 Roche Chile at a Glance . 86 Roche in Venezuela . 159 Healthcare in Chile . 87 Sustainability Initiatives . 161 Roche in Chile . 87 Sustainability Initiatives . 89 6 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 7 This Report At Roche, we are dedicated to doing good business that contrib- Roche’s most recent sustainability report, 2015 Global Report,(1) utes to a better world. Everything we do as a company is guided follows the GRI G4 standards, and its content is guided by an by our commitment to scientific rigor, unassailable ethics, and updated global materiality assessment. The regional office of access to medical innovations for all. We value transparency Roche in Latin America(2) follows the Group’s approach, and and ethical management, and public reporting on our activities our second regional Sustainability Report is informed by the and results is an important tool for promoting both. The Group GRI G4 methodology. has been publishing a sustainability report for more than 10 years and has adopted the guidelines of the Global Reporting This report covers Roche’s economic, social, and environmental Initiative (GRI). impacts in Latin America for the two-year period from January 1, 2014 to December 31, 2015. The content covers the Pharmaceu- ticals Division in the 10 affiliates comprising the regional group: Argentina, Brazil, Central America and the Caribbean, Chile, Colombia, Ecuador, Mexico, Peru, Uruguay, and Venezuela. The data highlighted in this report are based on key performance in- dicators in all of the listed affiliates. We value transparency Roche believes sustainability is an on-going journey of continu- ous improvement. This report reflects a moment in time on that and ethical management, journey, and Roche is committed to strengthening and expanding its sustainability management processes and tools in the future. and public reporting on our activities and results (1) Roche Annual Report 2015: www.roche.com/gb15e.pdf is an important tool for (2) In this report, “Roche in Latin America” only refers to its Pharmaceuticals Division. promoting both. 8 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 9 Global Overview Roche at a Glance A global leader in innovation A sustainable company A great workplace Roche is the world’s largest biotech- Roche is committed to business Roche is driven by a shared set of nology company and a leader in re- practices that are sustainable, ethi- values including integrity, the cour- search-focused healthcare. cal and responsible to create long- age to reach beyond boundaries term value . and a passion for what we do. +100 #1 #1 #1 Countries in biotech in oncology and in hospital markets in vitro diagnostics 48.1 9.3 91,747 billion CHF(3) in sales billion CHF in Employees R&D investment (full-time equivalents) 29 70 40% Roche medicines on WHO new medical entities in Women Essential Medicines List clinical development in management roles 25,000,000 +300,000 Patients treated Patients in clinical trials with one of Roche’s top 25 selling products 2015 data Figures include Pharmaceutical and Diagnostics divisions. For further information: www.roche.com (3) Swiss francs 10 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 11 Who we are Innovation: it’s in our DNA. At Roche we have always worked across As the world’s largest biotech company, we develop breakthrough disciplines and geographies to drive scientific discovery and redefine medicines, improving the standard of care across oncology, im- what is possible to improve patients’ lives. munology, infectious diseases, ophthalmology and neuroscience. We are also the world leader in the in vitro diagnostics business. We work towards understanding how diseases differ down to the This track record allows us to build lasting and meaningful part- molecular level in order to develop new tests and medicines that nerships across the world with research academia and public prevent, diagnose and treat diseases that matter and bring them to healthcare institutions. the patients who need them. With our combined strengths in diag- nostics and pharmaceuticals, our personalised healthcare strategy We remain dedicated to the highest standards of quality, safety and aims to fit the right treatment to the right patient. integrity. Our legacy is based on respect for the individual, as well as the communities and the world we live in. Our values Integrity starts with me. Discovery starts with passion. We are consistently open, honest and genuine. We use our drive and commitment to energise, engage and in- spire others. Just as we expect it from ourselves and our colleagues, society expects that we live by high standards of integrity. Integrity starts Above all, our passion is to improve patients’ lives, and it is this with being honest with oneself and understanding one’s own passion that fuels our determination and enables us to persevere, strengths and weaknesses. It is also about interacting with others often over many years. Passion can express itself in highly visible in an open, genuine way. That is a must for building a strong re- ways – such as an enthusiastic speech or a persuasive presentation. lationship of trust with anyone, whether inside or outside Roche. It can also be low key – such as persistently repeating an experi- We must act ethically and honestly at all times. ment over and over again to determine whether an unexpected result was just an error or possibly an important new discovery. Success starts with courage. We are entrepreneurial, taking risks, experimenting and reaching beyond boundaries. Our business and strategy takes us often into uncharted territory. This also means that we must have the courage to take appropri- Above all, our passion ate risks in order to succeed. This means we need to think like entrepreneurs and be prepared to try new ways of doing things is to improve patients’ even if we are convinced that the traditional ways are right. We may not always feel comfortable about taking a minority view or lives, and it is this expressing criticism. Yet if we don’t speak up, we run the risk of not tackling necessary changes, whether out of complacency or passion that fuels our an ill-conceived desire for harmony. Being courageous will en- sure we can remain successful and stay ahead in the long run. determination and enables us to persevere, often over many years. 12 Roche Latin America 2014-2015 Sustainability Report Roche Latin America 2014-2015 Sustainability Report 13 Roche Group Profile Roche is a global healthcare pioneer advancing science for human- To date the Roche Group has helped to improve peoples’ health and ity.